Satsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society's 68th Annual Scientific Meeting

DURHAM, N.C., June 4, 2026 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing innovative treatments for people living with migraine, today announced that two abstracts highlighting findings from its clinical development program have been selected for presentation at the American Headache Society's (AHS) 68th Annual Scientific Meeting.